Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
29 mrt 2016 - 07:00
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma to host a webcast of the full dataset on the primary endpoint of its single-dose Phase II trial with ATIR101™
Bericht
~ Webcast Monday April 4, 2016 at 18:00 CET ~
Amsterdam, The Netherlands, March 29, 2016, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces it will host a webcast on Monday April 4, 2016 at 18:00 CET to discuss the full dataset on the primary endpoint (Transplant Related Mortality at 6 months post transplantation) of its single-dose Phase II trial (NCT01794299/EudraCT 2012-004461-41) with its lead product ATIR101™. During the webcast, the data will also be put into perspective with other current approaches in the literature for patients lacking a fully matched donor, such as the Baltimore approach using post-transplant cyclophosphamide.
The webcast will be hosted by Manfred Rüdiger, Chief Executive Officer and Jeroen Rovers, Chief Medical Officer, together with Dr. Denis-Claude Roy*, Professor of Medicine at the University of Montreal and principal investigator for the study.
To register for the webcast, please visit the homepage of Kiadis Pharma at: www.kiadis.com.
To view the webcast, please call the appropriate number below, 10 minutes prior to the start time:
The Netherlands: 020 716 8427
Toll-free The Netherlands: 0800 265 8619
Belgium: 02 401 2722
Toll-free Belgium: 0800 50 562
United Kingdom: 0203 139 4830
Toll-free United Kingdom: 0808 23 700 30
United States: 1718 873 9077
Toll-free United States: 1866 928 7517
Conference ID: 25282024#
The webcast will be conducted in English and viewers will have the opportunity to submit questions during the Q&A portion of the live webcast. A replay of the webcast will be made available on Kiadis Pharma’s website.
Gerelateerde downloads
Datum laatste update: 27 juli 2024